Abstract
We report a series of phenyl substituted pyridazin-3-ones substituted with morpholino-pyrimidines. The SAR of the phenyl was explored and their c-Met kinase and cell-based inhibitory activity toward c-Met driven cell lines were evaluated. Described herein is a potent c-Met inhibitor by structural modification of the parent morpholino-pyridazinone scaffold, with particular focus on the phenyl and pyrimidine substituents.
| Original language | English |
|---|---|
| Pages (from-to) | 5093-5097 |
| Number of pages | 5 |
| Journal | Bioorganic and Medicinal Chemistry Letters |
| Volume | 24 |
| Issue number | 21 |
| DOIs | |
| State | Published - 1 Nov 2014 |
Keywords
- c-Met inhibitor
- Cancer
- Pyridazin-3-one